As of 10:13 on February 20, 2025, the CSI Vaccine and Biotechnology Index rose strongly by 1.13%, with constituent stocks Yifang Biotech rising by 7.45%, Dizhe Pharmaceuticals rising by 6.93%, Shuanglu Pharmaceuticals rising by 4.37%, and Wanze Shares, Dongbao Bio and other stocks following suit. Bio-Vaccine ETF (562860) rose by 1.14%, and the intraday turnover has reached 6.5605 million yuan.

In terms of scale, the scale of Bio-Vaccine ETF has increased by 3.2427 million yuan in the past week, achieving significant growth.

It is worth noting that the valuation of the CSI Vaccine and Biotechnology Index tracked by the fund is at a historical low, with the latest price-to-book ratio PB being 2.95 times, which is lower than the index's 83.43% of the past five years, and the valuation cost-effectiveness is outstanding.

Data shows that as of January 27, 2025, the top ten weighted stocks in the CSI Vaccine and Biotechnology Index are Zhifei Bio, Wantai Bio, Watson Bio, Hualan Bio, BeiGene, Shandong Yaobo, Kangtai Bio, Tebao Bio, Ganli Pharmaceutical, and Fosun Pharma, and the top ten weighted stocks account for a total of 51.04%.

Recently, various provinces and cities have successively disclosed the 2025 livelihood projects and provincial fiscal budgets. According to statistics, as of now, more than a dozen provinces, including Beijing and Sichuan, have launched or plan to launch provincial-level free vaccination projects for human papillomavirus (HPV) vaccines for women of appropriate age.

Kaiyuan Securities predicts that with the successful completion of the Phase III clinical trials of the HPV vaccine and the release of production capacity, its indications will be expanded to the male population. In addition, with the continuous improvement of vaccination awareness among the target population, the scale of China's HPV vaccine market will continue to expand, and is expected to reach 62.54 billion yuan in 2031.

https://finance.eastmoney.com/a/202502203324640665.html